Peterlabs Holdings BhdXKLS:0171 47 EBIT per Share is RM0.01 as of Jun. 2025. GuruFocus rates XKLS:0171 with a GF Score™ of 47/100. Among 810 Drug Manufacturers companies, Peterlabs Holdings Bhd ranks better than 54.94% on this metric.
Peterlabs Holdings Bhd's EBIT per Share for the
three
months ended in Jun. 2025 was RM-0.01.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2025 was RM0.01.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Peterlabs Holdings Bhd's EBIT per Share or its related term are showing as below:
XKLS:0171's 3-Year EBIT Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.55 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
Peterlabs Holdings Bhd (XKLS:0171) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Peterlabs Holdings Bhd EBIT per Share Related Terms
Peterlabs Holdings Bhd EBIT per Share Historical Data
* Premium members only.
The historical data trend for Peterlabs Holdings Bhd's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was RM0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Peterlabs Holdings Bhd (XKLS:0171) has a EBIT per Share of RM0.01 as of Jun. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Peterlabs Holdings Bhd and its competitors. According to the industry distribution chart, Peterlabs Holdings Bhd ranks #365 out of 810 companies in the Drug Manufacturers industry, placing it in the top 45.1%.
Is Peterlabs Holdings Bhd's EBIT per Share too high?
Peterlabs Holdings Bhd's current EBIT per Share is RM0.01. Based on the distribution chart, Peterlabs Holdings Bhd ranks #365 out of 810 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Peterlabs Holdings Bhd has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Peterlabs Holdings Bhd's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Peterlabs Holdings Bhd ranks #365 out of 810 companies for EBIT per Share. This puts Peterlabs Holdings Bhd in the upper half of its industry. The industry median EBIT per Share is 7.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.55, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Peterlabs Holdings Bhd and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Peterlabs Holdings Bhd's current EBIT per Share is RM0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Peterlabs Holdings Bhd stock overvalued right now?
Peterlabs Holdings Bhd (XKLS:0171) has a current EBIT per Share of RM0.01. The current EBIT per Share is RM0.01. Peterlabs Holdings Bhd's overall GF Score™ is 47/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Peterlabs Holdings Bhd (XKLS:0171), the current EBIT per Share is RM0.01 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Peterlabs Holdings Bhd is engaged in the manufacturing, distribution, export, and trading of animal health and nutrition products. The Group offers biosecurity and disinfectants, compound feed supplements, feed additives, nutritional premixes, pharmaceuticals, and water-soluble supplements, as well as farm management, technical advisory services, raw material analysis, and feed formulation. Its segments are Manufacturing, which covers the manufacturing and distribution of animal health and nutrition products; Trading, which involves the trading and distribution of animal health and nutrition products and consumer goods, and contributes the majority of its revenue; and Others, which provides investment holding services. The company operates in Malaysia and internationally.
47GF Score
Get the complete analysis for XKLS:0171
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:0171 has been successfully added to your 
